Monday February 19th 2018

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

Conclusions: The emerging safety, tolerability, and PK of BIIB033 support advancing BIIB033 into phase II clinical development as a potential treatment for CNS demyelination disorders. Classification of evidence: This study provides Class I evidence that BIIB033 is well tolerated and safe (serious adverse event rate 0%, 95% confidence interval 0–7.6%). (Source: Neurology Neuroimmunology and Neuroinflammation)

Link:  

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

Leave a Comment

More from category

What side effects can result from interferon?
What side effects can result from interferon?

Interferon is used to treat several health conditions, but it has a range of side effects. We look at how these vary in [Read More]

FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS
FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS

Glatopa 40 mg/mL joins already-approved Glatopa 20 mg/mL, a glatiramer acetate generic for treatment of relapsing forms [Read More]

DIY faecal transplants carry risks including HIV and hepatitis, warn experts
DIY faecal transplants carry risks including HIV and hepatitis, warn experts

Faecal transplants have been used in medical settings to tackle superbugs, but following YouTube videos at home is too [Read More]

High blood pressure drug may also help prevent onset of type 1 diabetes
High blood pressure drug may also help prevent onset of type 1 diabetes

A drug commonly used to control high blood pressure may also help prevent the onset of type 1 diabetes in up to 60 [Read More]

Eye and balance exercises may ease multiple sclerosis symptoms
Eye and balance exercises may ease multiple sclerosis symptoms

Reuters Health - People with multiple sclerosis who do balance and eye movement exercises may feel steadier on their [Read More]